Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and six months ended June 30, 2024 and provided a business update. Highlights from the second quarter of 2024 and subsequent weeks included the following: Total revenues for the second quarter of 2024 were $7.8 million, a 34% increase from the same period of the prior year Cash ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Market LLC Preferred Stock Purchase Rights The Nasdaq Stock Market LLC Warrants to purchase common stock BFRIW The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ...

Forward-Looking Statements WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the launch of its FDAapproved RhodoLED XL, a red light emitting LED lamp. This innovative device represents a significant advancement in the treatment of PDT with state-of-the-art engineering, robust but sleek construction and an intuitive user interface. It is designed to be simple to maneuv ...

WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the launch of its FDAapproved RhodoLED XL, a red light emitting LED lamp. This innovative device represents a significant advancement in the treatment of PDT with state-of-the-art engineering, robust but sleek construction and an intuitive user interface. It is designed to be simple to maneuver and able to accommodate ...

Biofrontera Inc. (NASDAQ:BFRI) Q1 2024 Earnings Conference Call May 16, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - Chief Executive Officer, Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Bruce Jackson - The Benchmark Company Operator Welcome to the Biofrontera Inc. First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in list ...

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2024 and provided a business update. ● Total revenues for the first quarter of 2024 were $7.9 million, a 9% decrease from the same period of the prior year primarily dr ...

Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Market LLC Preferred Stock Purchase Rights The Nasdaq Stock Market LLC Warrants to purchase common stock BFRIW The Nasdaq Stock Market LLC For the quarterly period ended March 31, 2024 For the transition period from to Delaware 47-3765675 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Not Applicable (Former name, form ...

Financial Data and Key Metrics Changes - Total revenues for 2023 were $34.4 million, a growth of approximately 19% compared to $28.7 million for 2022, primarily driven by higher Ameluz sales volume and a restructured discount program [53][45] - Adjusted EBITDA for the fourth quarter of 2023 was negative $3.2 million, an improvement from negative $4.4 million for the fourth quarter of 2022, reflecting higher revenues partially offset by increased SG&A costs [35] - Net income for the fourth quarter of 2023 was $3.5 million or $1.65 per share, compared to a net loss of $2.8 million or a loss of $2.16 per share for the prior-year quarter [52] Business Line Data and Key Metrics Changes - The company placed 123 BF-RhodoLED lamps at physician offices during 2023, an increase of 86% from 66 in 2022, indicating strong adoption of Ameluz PDT [45] - Cost of revenues increased to $17.4 million for 2023 from $15.2 million in 2022, primarily driven by increased Ameluz volume [36] Market Data and Key Metrics Changes - The company expects to achieve two-digit growth in revenue compared to 2023 and anticipates being cash flow positive within approximately 12 to 18 months [62] - The company has secured financing of $8 million and expects another tranche of $8 million in Q2 2024 to support ongoing commercial activities and clinical development [28] Company Strategy and Development Direction - The company is optimizing its customer-facing teams and shifting resources from a sales force-focused organization to invest in marketing and support functions [46] - The company plans to launch the larger RhodoLED XL lamp in Q2 2024, which will allow treatment of larger skin areas, crucial for future growth [30] Management Comments on Operating Environment and Future Outlook - Management highlighted transformational changes in 2023 that have improved the company's status and future outlook compared to the previous year [76] - The company expects to maintain a growth trajectory similar to the past couple of years, with a compound annual growth rate (CAGR) of 22% since 2020 [73] Other Important Information - The company settled arbitration regarding the acquisition of the Xepi asset, removing significant liabilities from its balance sheet [29] - The U.S. Patent and Trademark Office granted a new patent related to a less painful PDT protocol, extending product protection until 2040 [47] Q&A Session Summary Question: What is the enrollment status for the acne trial? - Approximately 50% to 60% of patients are currently enrolled, with completion expected by the end of the year and data available in the middle of next year [38] Question: What about the peripheral AK study? - The enrollment is similar, with data expected slightly after the acne trial due to longer patient duration in the trial [64] Question: Any changes to the sales force and turnover? - The sales force has been slightly reduced to focus on growing other service functions, with current turnover being below the industry average [11][19] Question: What are the expectations for sales growth this year? - A reasonable target for sales growth is around 19%, consistent with the growth seen over the past couple of years [73]

Our principal licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLEDlamp series, for PDT (when used together, "Ameluz PDT"). In the United States, the PDT treatment is used for the lesion-directed and fielddirected treatment of actinic keratoses ("AK") of mild-to-moderate severity on the face and scalp. AKs are premalignant lesions of the skin that can potentially develop into skin cancer (squamous cell carcinoma) if left untreated.International treatment ...

Biofrontera Inc. (NASDAQ:BFRI) Q3 2023 Earnings Conference Call November 10, 2023 10:00 AM ET Company Participants Tirth Patel - IR Hermann Luebbert - Chairman, CEO and Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera Inc. Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the c ...